# A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

> **NCT05904457** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 32 (estimated)

## Conditions studied

- Solid Tumors
- Advanced Solid Tumors
- Metastatic Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT05904457
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-02
- **Primary completion:** 2025-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904457, "A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05904457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*